WASHINGTON--(BUSINESS WIRE)--Delphi Genetics SA (“Delphi”) announced today at the BIO convention the launching of StabyExpress strains with a completely sequenced genome. These strains contain different mutations including the genetic locus to use StabyExpress allowing the industrial scale production of high yield recombinant proteins without using antibiotics. Working with these completely sequenced strains allows for the first time the production of biopharmaceutical molecules in a completely characterized genetically production microbial host without using antibiotic resistance genes.
